Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT · Real-Time Price · USD
0.7822
-0.0098 (-1.24%)
At close: Oct 9, 2026, 4:00 PM EDT
0.7704
-0.0118 (-1.51%)
After-hours: Oct 9, 2026, 7:49 PM EDT
Lakewood-Amedex Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel class of antimicrobials, Bisphosphocins, is advancing in clinical development for diabetic foot ulcer infections, showing rapid bacterial kill, low resistance risk, and strong preclinical and early clinical results. A phase IIA trial is set for 2024, with broader pipeline and IP strength supporting future growth.